Qianqian Liu
Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
Department of Population Health Sciences · UT Health San Antonio, USA
Qianqian Liu contributed biostatistical work to the 2018 Kraig et al. paper — one of the earliest placebo-controlled human pilot trials testing whether low-dose rapamycin (1 mg/day) is safe and tolerable in healthy older adults (70-95 years old), run out of UT Health San Antonio's Barshop Institute for Longevity and Aging Studies.
The trial found short-term rapamycin was generally well tolerated, with only mild hematologic changes and no worsening of glucose metabolism, cognition, or physical performance — a result that helped pave the way for the larger human longevity trials of mTOR inhibition that followed.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. KRA2018 Contributed biostatistical work to the UT Health San Antonio pilot trial showing short-term low-dose rapamycin is safe and tolerable in healthy older adults, an early human proof-of-concept for mTOR-inhibition longevity research. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Qianqian Liu.
ShowHide
- Adriana D. Benavides Immunologist who worked at UT Health San Antonio and the Children's Hospital of Philadelphia, and a co-author of the first small safety trial of rapamycin in healthy older people
- Dean L. Kellogg Jr. A geriatrician who co-leads clinical trials of rapamycin in older adults at the Barshop Institute, with a focus on safety and cardiovascular effects.
- Ellen Kraig Immunologist at UT Health San Antonio who studies how aging changes immune regulation and who led the first small safety trial of rapamycin in healthy older people at the Barshop Institute
- Martin A. Javors Pharmacologist and professor at UT Health San Antonio who directs an analytical laboratory for biochemical and drug measurements, and a co-author of rapamycin studies in mice and in older people
- Nicolas Musi Endocrinologist and aging researcher who directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center at Cedars-Sinai, and who studies how aging drives insulin resistance, frailty and senescence
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.